Ziprasidone as an Augmenting Agent in the Treatment of Anxiety-Spectrum Disorders

CNS Spectrums ◽  
2005 ◽  
Vol 10 (3) ◽  
pp. 176-179 ◽  
Author(s):  
Daniel L. Crane
Keyword(s):  
Anxiety Disorders ◽  
Selective Serotonin Reuptake Inhibitors ◽  
The United States ◽  
Pharmacologic Treatment ◽  
Obsessive Compulsive ◽  
Health Concerns ◽  
Compulsive Disorder ◽  
The Past ◽  
Augmentation Strategies ◽  
Spectrum Disorders

AbstractAnxiety disorders are currently one of the most common health concerns in the United States. Overall, they are the single largest cost to the healthcare system. They are also underdiagnosed and undertreated. Selective serotonin reuptake inhibitors and benzodiazepines appear to be the most common pharmacologic treatment approaches. Unfortunately, not all patients respond to these treatments. Many augmentation strategies have been tried in the past with varying levels of success or safety. This article describes a safe and highly effective augmentation technique in patients suffering from some of the most serious and debilitating forms of anxiety disorders, namely obsessive-compulsive disorder and panic disorder.

scholarly journals Agomelatine Augmentation of Escitalopram Therapy in Treatment-Resistant Obsessive-Compulsive Disorder: A Case Report

2012 ◽  
Vol 2012 ◽  
pp. 1-4 ◽  
Author(s):  
Domenico De Berardis ◽  
Nicola Serroni ◽  
Stefano Marini ◽  
Giovanni Martinotti ◽  
Francesca Ferri ◽  
...  
Keyword(s):  
Obsessive Compulsive Disorder ◽  
Chronic Condition ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Atypical Antipsychotics ◽  
Young Female ◽  
Treatment Resistant ◽  
First Line ◽  
Obsessive Compulsive ◽  
Compulsive Disorder ◽  
Augmentation Strategies

Obsessive-compulsive disorder (OCD) is a chronic condition characterized by obsessions or compulsions that cause distress or interfere with functioning. Selective serotonin reuptake inhibitors are the first-line strategy in the treatment of OCD, but approximately 40% to 60% of patients with OCD fail to respond to them. Several augmentation strategies have been proposed, including the use of atypical antipsychotics and antidepressant combinations. In the present paper we describe the case of a young female patient suffering from severe treatment-resistant OCD who remitted as a result of agomelatine augmentation of escitalopram therapy.

The Role of Glutamate in Anxiety and Related Disorders

CNS Spectrums ◽  
2005 ◽  
Vol 10 (10) ◽  
pp. 820-830 ◽  
Author(s):  
Bernadette M. Cortese ◽  
K. Luan Phan
Keyword(s):  
Anxiety Disorders ◽  
Metabotropic Glutamate Receptors ◽  
Selective Serotonin Reuptake Inhibitors ◽  
The United States ◽  
Current Treatment ◽  
Health Concern ◽  
Compulsive Disorder ◽  
Fear Potentiated Startle ◽  
Fear And Anxiety

AbstractAnxiety, stress, and trauma-related disorders are a major public health concern in the United States. Drugs that target the γ-aminobutyric acid or serotonergic system, such as benzodiazepines and selective serotonin reuptake inhibitors, respectively, are the most widely prescribed treatments for these disorders. However, the role of glutamate in anxiety disorders is becoming more recognized with the belief that drugs that modulate glutamatergic function through either ionotropic or metabotropic glutamate receptors have the potential to improve the current treatment of these severe and disabling illnesses. Animal models of fear and anxiety have provided a method to study the role of glutamate in anxiety. This research has demonstrated that drugs that alter glutamate transmission have potential anxiolytic action for many different paradigms including fear-potentiated startle, punished responding, and the elevated plus maze. Human clinical drug trials have demonstrated the efficacy of glutamatergic drugs for the treatment of obsessive-compulsive disorder, posttraumatic stress disorder, generalized anxiety disorder, and social phobia. Recent data from magnetic resonance imaging studies provide an additional link between the glutamate system and anxiety. Collectively, the data suggest that future studies on the mechanism of and clinical efficacy of glutamatergic agents in anxiety disorders are appropriately warranted.

Obsessive Compulsive Spectrum Disorders in Children and Adolescents

2012 ◽  
Author(s):  
Eric A. Storch ◽  
Omar Rahman ◽  
Mirela A. Aldea ◽  
Jeannette M. Reid ◽  
Danielle Bodzin ◽  
...  
Keyword(s):  
Children And Adolescents ◽  
Clinical Characteristics ◽  
Body Dysmorphic Disorder ◽  
Repetitive Behaviors ◽  
Future Research ◽  
Obsessive Compulsive ◽  
Compulsive Disorder ◽  
Augmentation Strategies ◽  
Spectrum Disorders

This chapter reviews the literature on obsessive compulsive spectrum disorders (i.e., obsessive compulsive disorder, body dysmorphic disorder, trichotillomania, Tourette syndrome, and varied body-focused repetitive behaviors) in children and adolescents. For each disorder, data on phenomenology, associated clinical characteristics, etiology, and treatment are reviewed. The chapter concludes with a discussion of future research and clinical directions, such as novel augmentation strategies, diagnostic classification of obsessive compulsive spectrum disorders, and methods of maximizing treatment outcome.

Obsessions, Compulsions, Clozapine, and Risperidone

CNS Spectrums ◽  
1997 ◽  
Vol 2 (3) ◽  
pp. 26-36 ◽  
Author(s):  
Robert W. Baker ◽  
Paul D. Bermanzdhn ◽  
Donna Ames Wirshing ◽  
K. N. Roy Dhengappa
Keyword(s):  
United States ◽  
Obsessive Compulsive Disorder ◽  
Serotonin Reuptake ◽  
Antipsychotic Drugs ◽  
The United States ◽  
Serotonin Reuptake Inhibitors ◽  
Obsessive Compulsive ◽  
Compulsive Disorder ◽  
The Past ◽  
First Time

In the past decade, clozapine, risperidone, and olanzapine were marketed for the first time in the United States, and other new antipsychotic drugs are expected to follow soon. Also within the past decade, the efficacy of serotonin-reuptake inhibitors (SRIs) has been demonstrated in patients with obsessive-compulsive disorder (OCD) and the serotonin hypothesis of OCD has been articulated clearly.

Obsessive-Compulsive Disorder and Its Potential Subtypes

CNS Spectrums ◽  
2000 ◽  
Vol 5 (S4) ◽  
pp. 40-46 ◽  
Author(s):  
Donald W. Black
Keyword(s):  
Obsessive Compulsive Disorder ◽  
Serotonin Receptor ◽  
Late Onset ◽  
Age At Onset ◽  
The United States ◽  
Obsessive Compulsive ◽  
Molecular Genetic Study ◽  
Compulsive Disorder ◽  
Eeg Abnormalities ◽  
Spectrum Disorders

AbstractThis manuscript summarizes presentations by an international panel of experts, representing Brazil, Israel, Italy, Mexico, Portugal, Spain, and the United States, at a symposium on obsessive-compulsive disorder (OCD) and its possible subtypes. Presentations concerned both OCD proper, as well as putative obsessive-compulsive-spectrum disorders (autistic disorders, eating disorders, pathological gambling, and schizo-obsessive disorder). Projects discussed included a study assessing impulsive temperament in eating disorder patients, a study on serotonin receptor sensitivity in autism, a study of sleep EEG abnormalities in OCD, a study of dissociation in pathological gamblers, papers on aspects of schizo-obsessive patients, a study addressing biological alterations in OCD, data from a new family study on OCD, data from a molecular genetic study of OCD, a factor analytic study of Tourette disorder, a study hypothesizing the existence of an OCD continuum, and, finally, a paper on early- vs late-onset OCD. General discussion followed leading to a consensus that 1) OCD is likely heterogeneous with multiple subtypes; 2) division of patients by age-at-onset probably represents a robust and valid subtyping scheme; 3) the presence of schizophrenic features probably identifies a valid subtype; 4) the validation of subtypes in the future will be informed by both family-genetic studies, as well as studies of biological alterations in OCD; and 5) the study of obsessive-compulsive spectrum disorders adds to our understanding of the OCD phenomenon, and helps in our search to identify valid subtypes.

scholarly journals CASE STUDY OF PERSON WITH BODY DYSMORPHIC DISORDER

2016 ◽  
Vol 4 (7) ◽  
pp. 102-108
Author(s):  
M. Senthil
Keyword(s):  
Selective Serotonin Reuptake Inhibitors ◽  
Body Dysmorphic Disorder ◽  
Supportive Therapy ◽  
Family Intervention ◽  
Somatoform Disorder ◽  
Pharmacologic Treatment ◽  
Body Parts ◽  
Obsessive Compulsive ◽  
Compulsive Disorder

This article presents a case study of client with Body dysmorphic disorder. Body dysmorphic disorder is an increasingly recognized somatoform disorder, clinically distinct from obsessive-compulsive disorder, eating disorders, and depression. Patients with body dysmorphic disorder are preoccupied with an imagined deficit in the appearance of one or more body parts, causing clinically significant stress, impairment, and dysfunction. The preoccupation is not explained by any other psychiatric disorder. Patients present to family physicians for primary care reasons and aesthetic or cosmetic procedures. Cosmetic correction of perceived physical deficits is rarely an effective treatment. Pharmacologic treatment with selective serotonin reuptake inhibitors and non-pharmacologic treatment with cognitive behavior therapy are effective. Body dysmorphic disorder is not uncommon, but is often misdiagnosed. Recognition and treatment are important because this disorder can lead to disability, depression, and suicide. Psychiatric social work assessment and intervention was provided to the person with Body dysmorphic disorder, focusing on to building for change in misbelieve and strengthening commitment to change. The psycho social intervention was provided to the patients and his family members. Sessions on Admission counseling, Family intervention, Supportive therapy, Psycho education, role play, reminiscence, Pre discharge counseling, Discharge Counseling and Social Group Work was conducted. At the end of the therapy, the client knowledge about the illness and coping skills has improved.

Overview of Diagnosis and Drug Treatments of Anxiety Disorders

CNS Spectrums ◽  
2005 ◽  
Vol 10 (1) ◽  
pp. 49-56 ◽  
Author(s):  
David J. Nutt
Keyword(s):  
Anxiety Disorder ◽  
Anxiety Disorders ◽  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin ◽  
Obsessive Compulsive ◽  
Compulsive Disorder ◽  
Drug Treatments ◽  
The Common

AbstractAnxiety disorders are common and often disabling. They fall into five main categories: panic disorder, social anxiety disorder, generalized anxiety disorder, obsessive-compulsive disorder and posttraumatic stress disorder, each of which have characteristic symptoms and cognitions. All anxiety disorders respond to drugs and psychological treatments. This review will focus on drug treatments. Recent research has emphasized the value of antidepressants especially the selective serotonin reuptake inhibitors, benzodiazepines, and related sedative-like compounds. The common co-existence of depression with all of the anxiety disorders means that the selective serotonin reuptake inhibitors are now generally considered to be the first-line treatments but the benzodiazepines have some utility especiaRy in promoting sleep and working acutely to reduce extreme distress.

scholarly journals The Social Costs of Anxiety Disorders

1995 ◽  
Vol 166 (S27) ◽  
pp. 19-22 ◽  
Author(s):  
Andrew C. Leon ◽  
Laura Portera ◽  
Myrna M. Weissman
Keyword(s):  
Mental Health ◽  
Panic Disorder ◽  
Anxiety Disorders ◽  
Indirect Costs ◽  
The United States ◽  
Social Costs ◽  
Emergency Rooms ◽  
Obsessive Compulsive ◽  
Compulsive Disorder ◽  
The Social

Background. The social costs of anxiety disorders, which afflict a substantial proportion of the general population in the United States, are considered.Method. Data from the National Institute of Mental Health (NIMH) Epidemiological Catchment Area Program were analysed.Results. Over 6% of men and 13% of women in the sample of 18 571 had suffered from a DSM–III anxiety disorder in the past six months. Nearly 30% of those with panic disorder had used the general medical system for emotional, alcohol or drug-related problems in the six months prior to the interview. Those with anxiety disorders were also more likely to seek help from emergency rooms and from the specialised mental health system. Men with panic disorder, phobias or obsessive–compulsive disorder in the previous six months are more likely to be chronically unemployed and to receive disability or welfare.Discussion. Once correctly diagnosed there are safe and effective psychopharmacologic and behavioural treatments for the anxiety disorders. Nevertheless the burden of anxiety disorders extends beyond the direct costs of treatment to the indirect costs of impaired social functioning.

Sign in / Sign up

Export Citation Format

Share Document